Sou Hu Cai Jing·2025-08-11 01:53Group 1 - The core issue involves tax self-inspection results disclosed by two companies, Daon Co., Ltd. and Huason Pharmaceutical, due to discrepancies in the tax treatment of convertible bond interest expenses [1][3][7] - Daon Co., Ltd. needs to pay a total of 16.15 million yuan, which includes 11.87 million yuan in corporate income tax and 4.27 million yuan in late fees [3][4] - Huason Pharmaceutical is required to pay a total of 10.02 million yuan, comprising 7.17 million yuan in corporate income tax and 2.84 million yuan in late fees [1][7][8] Group 2 - Both companies confirmed that the tax payment issues do not involve prior accounting errors and will not require restatement of previous financial data [4][8] - The tax payments will impact the net profit attributable to shareholders for the year 2025, with Daon Co., Ltd. expecting a reduction of 16.15 million yuan and Huason Pharmaceutical anticipating a reduction of 10.02 million yuan [4][8] - The companies have emphasized their commitment to enhancing supervision and management of tax-related matters to protect the interests of shareholders [8]